Trade Haven Hub - Investing and Stock News
  • Investment Tips
  • Trade Tips
  • Crypto News
  • Economy News
  • Stock Market
  • Investment Tips
  • Trade Tips
  • Crypto News
  • Economy News
  • Stock Market
No Result
View All Result
Trade Haven Hub - Investing and Stock News
No Result
View All Result
Home Trade Tips

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

admin by admin
May 27, 2025
in Trade Tips
0
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the ‘AGM’) will be webcast on May 28, 2025, at 4:30 p.m. EDT.

Cardiol Therapeutics’ 2025 AGM

When: May 28, 2025, at 4:30 p.m. EDT
Where: Virtual meeting only via live audio webcast online at: web.lumiagm.com/226536161

Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com/investors/events-presentations/.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, and the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253470

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com
Previous Post

FPX Nickel and JOGMEC Initiate Exploration at the Expanded Klow Property in British Columbia

Next Post

Bitcoin Well Announces Nostr Integration; Including Bitcoin Purchases Via Direct Message

Next Post
Bitcoin Well Announces Nostr Integration; Including Bitcoin Purchases Via Direct Message

Bitcoin Well Announces Nostr Integration; Including Bitcoin Purchases Via Direct Message

  • Trending
  • Comments
  • Latest
Pepe Price Climbs 43% With Only 21 Days Left to Buy MIND of Pepe Cheap, Nearly $9m Raised 

Pepe Price Climbs 43% With Only 21 Days Left to Buy MIND of Pepe Cheap, Nearly $9m Raised 

May 9, 2025
Bitcoin Price Prediction: At $103,688 BTC Shows Unstoppable Weekly Growth of 7.6% – Could We See a New All-Time High Before June?

Bitcoin Price Prediction: At $103,688 BTC Shows Unstoppable Weekly Growth of 7.6% – Could We See a New All-Time High Before June?

May 10, 2025
Murchison South Increases to 67koz Gold Across Two Pits

Murchison South Increases to 67koz Gold Across Two Pits

May 13, 2025
Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

May 8, 2025
Earn Bitcoin Without Hardware: Why HashFly Leads the Cloud Mining Space

Earn Bitcoin Without Hardware: Why HashFly Leads the Cloud Mining Space

0
Quantum Computing: its Evolution and its Potential Future

Quantum Computing: its Evolution and its Potential Future

0
Quantum Computing: its Evolution and its Potential Future

Quantum Computing: its Evolution and its Potential Future

0
Air Direct Capture – Reducing CO2 from the Atmosphere

Air Direct Capture – Reducing CO2 from the Atmosphere

0
Earn Bitcoin Without Hardware: Why HashFly Leads the Cloud Mining Space

Earn Bitcoin Without Hardware: Why HashFly Leads the Cloud Mining Space

June 5, 2025
Bitcoin Miner BitMine Raises $18M to Buy Bitcoin, Stock Lists on NYSE American

Bitcoin Miner BitMine Raises $18M to Buy Bitcoin, Stock Lists on NYSE American

June 5, 2025
SEC Scores $1.1M Court Victory After Crypto Scam Defendant Fails to Respond

SEC Scores $1.1M Court Victory After Crypto Scam Defendant Fails to Respond

June 5, 2025
Ethereum Foundation Reworks Treasury Strategy — What Changes to Expect

Ethereum Foundation Reworks Treasury Strategy — What Changes to Expect

June 5, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    Earn Bitcoin Without Hardware: Why HashFly Leads the Cloud Mining Space

    Earn Bitcoin Without Hardware: Why HashFly Leads the Cloud Mining Space

    June 5, 2025
    Bitcoin Miner BitMine Raises $18M to Buy Bitcoin, Stock Lists on NYSE American

    Bitcoin Miner BitMine Raises $18M to Buy Bitcoin, Stock Lists on NYSE American

    June 5, 2025
    SEC Scores $1.1M Court Victory After Crypto Scam Defendant Fails to Respond

    SEC Scores $1.1M Court Victory After Crypto Scam Defendant Fails to Respond

    June 5, 2025
    Ethereum Foundation Reworks Treasury Strategy — What Changes to Expect

    Ethereum Foundation Reworks Treasury Strategy — What Changes to Expect

    June 5, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 tradehavenhub.com | All Rights Reserved

    No Result
    View All Result
    • Investment Tips
    • Trade Tips
    • Crypto News
    • Economy News
    • Stock Market

    Copyright © 2025 tradehavenhub.com | All Rights Reserved